aTyr Reports Results of ATYR1923 in P-ll Study for COVID-19 Patients with Severe Respiratory Complications

 aTyr Reports Results of ATYR1923 in P-ll Study for COVID-19 Patients with Severe Respiratory Complications

aTyr Reports Results of ATYR1923 in P-ll Study for COVID-19 Patients with Severe Respiratory Complications

Shots:

  • The P-ll study involves assessing of ATYR1923 (1.0 & 3.0 mg/kg) vs PBO in 32 hospitalized COVID-19 patients in the ratio of (1:1:1) with severe respiratory complications who do not require mechanical ventilation in the US and Puerto Rico
  • Result: the study met its 1EPs of safety, demonstrating that ATYR1923 (single dose, IV) was safe and well-tolerated in both treatment groups, with no SAEs, median time to recovery @3.0 mg/kg dose (5.5 vs 6 days); recovery by day 6 (83% vs 56%); median time to recovery @1.0 mg/kg dose (7days)
  • The company is developing the therapy for patients with inflammatory lung diseases

Click here ­to­ read full press release/ article | Ref: Atyr Pharma | Image: American College of Cardiology

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post